Squibb Company (NYSE:BMY) and Five Prime Therapeutics, Inc.
(Nasdaq:FPRX) today announced that they have entered into an exclusive
clinical collaboration agreement to evaluate the safety, tolerability
and preliminary efficacy of combining Opdivo (nivolumab),
Bristol-Myers Squibb’s investigational PD-1 (programmed death-1) immune
checkpoint inhibitor, with FPA008, Five Prime’s monoclonal antibody that
inhibits colony stimulating factor-1 receptor (CSF1R). The Phase 1a/1b
study will evaluate the combination of Opdivo and FPA008 as a
potential treatment option for patients with non-small cell lung cancer
(NSCLC), melanoma, head and neck cancer, pancreatic cancer, colorectal
cancer and malignant glioma.
for Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo (nivolumab) and FPA008 in Six Tumor Types investment picks